Skf83959

Manufactured by Bio-Techne

SKF83959 is a selective and potent dopamine D1 receptor agonist. It functions by activating the dopamine D1 receptor, which is involved in various physiological processes. The product is intended for research use only and its specific applications should be evaluated by the user.

Automatically generated - may contain errors

Lab products found in correlation

Raclopride, by Merck Group (2 mentions) Quinpirole, by Bio-Techne (2 mentions) Pirenzepine, by Merck Group (2 mentions) Ketanserin, by Merck Group (2 mentions) Sch23390, by Merck Group (2 mentions) Acetylcholine, by Merck Group (2 mentions) Sulpiride, by Bio-Techne (1 mentions) Yohimbine, by Bio-Techne (1 mentions) L 741 626, by Bio-Techne (1 mentions) Sch23390, by Bio-Techne (1 mentions) L 745870, by Bio-Techne (1 mentions) Dopamine hydrochloride, by Merck Group (1 mentions)

3 protocols using skf83959

Pharmacological Modulation of Cell Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

For the cell culture assays, the following pharmacologic reagents were used: 5-HT (Sigma, St. Louis, MO), acetylcholine (Sigma, St. Louis, MO), DA (Sigma, St. Louis, MO), the 5-HT2A/C receptor antagonist ketanserin (Sigma, St. Louis, MO), the M1 muscarinic receptor antagonist pirenzepine (Sigma, St. Louis, MO), the D2-like receptor agonist quinpirole (Tocris Biosciences, Minneapolis, MN) and the D1-like receptor agonist SKF83959 (Tocris Biosciences, Minneapolis, MN).
For the behavioral studies, SKF83959 (Tocris Biosciences, Minneapolis, MN) was dissolved in 0.9% saline solution at 0.2 mg/cc (1 mg/kg) and injected intraperitoneally (i.p.). For the dose response experiments, additional doses of SKF83959 (0.05 and 0.25 mg/kg) were also used. The D2-like receptor antagonist raclopride (Sigma, St. Louis, MO) was used at 0.5 mg/kg and the D1-like receptor antagonist SCH23390 (Sigma, St. Louis, MO) was used at 0.01 and 0.25 mg/kg.

Frederick A.L., Yano H., Trifilieff P., Vishwasrao H.D., Biezonski D., Mészáros J., Sibley D.R., Kellendonk C., Sonntag K.C., Graham D.L., Colbran R.J., Stanwood G.D, & Javitch J.A. (2015). Evidence against dopamine D1/D2 receptor heteromers. Molecular psychiatry, 20(11), 1373-1385.

+ Open protocol

+ Expand

Pharmacological Modulation of Cell Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

+ Open protocol

+ Expand

Dopamine Receptor Modulation of Motor Activity

Check if the same lab product or an alternative is used in the 5 most similar protocols

Dopamine hydrochloride (Sigma-Aldrich, Inc., St. Louis, MO) was bath applied in separate experiments at 1 µM, 3 µM, 10 µM, 30 µM, 100 µM, and 300 µM to determine dose-dependent effects on motor activity. The receptor-selective agonists we used included SKF 81297 for D₁-like receptors (10–50 µM; Tocris, Minneapolis, MN); quinpirole for D₂-like receptors (10–50 µM; Tocris); and the D₁/D₂ receptor co-agonist SKF 83959 (10–50 µM; Tocris). For dopamine receptor antagonists we used the D₁-like antagonist SCH-23390 (10 µM; Tocris); the D₂-like antagonists sulpiride (20 µM) and L-741626 (12 µM); the selective D₃ receptor antagonist SB 27701A (5 µM; Tocris); the selective D₄ receptor antagonist L-745870 (5 µM; Tocris). We also used the α₂ adrenergic receptor antagonist, yohimbine (2–4 µM; Tocris). Endogenous dopamine levels were manipulated with the DAT inhibitor GBR-12909 (10 µM; Hello Bio, Princeton, NJ) and the monoamine oxidase A and B inhibitor bifemelane (50 µM; Tocris).

Sharples S.A., Burma N.E., Borowska-Fielding J., Kwok C.H., Eaton S.E., Baker G.B., Jean-Xavier C., Zhang Y., Trang T, & Whelan P.J. (2020). A dynamic role for dopamine receptors in the control of mammalian spinal networks. Scientific Reports, 10, 16429.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!